New blood vessels: the repair signal behind BPC-157, TB-500 and GHK-Cu

Nothing in your body heals without a blood supply. A torn tendon, a strained muscle, skin that won’t close — the cells that do the rebuilding show up, and the first thing they need is fresh plumbing. Oxygen. Fuel. A way in and a way out. Your body lays down new blood vessels into the damaged spot on purpose, so the repair crew can actually get to work. The plain name for that is angiogenesis: new blood vessels growing in.

Here’s why the word is worth your time. Three of the most-talked-about recovery peptides — BPC-157, TB-500 and GHK-Cu — all lean on the same idea. Give the body a stronger signal to build that plumbing, and it repairs faster and more completely. Same trick, three molecules. If they work the way the early science hints, that is not a small thing.

What that plumbing could do for you

Think about the tissues that never seem to heal right. Tendons. Ligaments. The old muscle tear that flares up two years later. There’s a reason those are the stubborn ones: they have a thin blood supply to begin with. Thin supply, slow repair. It’s close to a rule.

So the pitch writes itself. Push more plumbing into a spot that’s starved of it, and the repair crew finally gets what it needs — the debris gets cleared, the rebuilding cells get delivered, and the timeline shortens. In animal injuries, that is roughly what these peptides do: they reach the wound, drive new vessels in, and the tissue closes faster. If you’ve ever spent eight months rehabbing a shoulder that should have taken three, you already feel the appeal.

That’s the upside, and at the class level it’s a genuinely exciting one. A signal that tells starved tissue to build itself a better blood supply is about as close to the recovery dream as a single mechanism gets.

Three peptides, one trick

The interesting part is that three quite different molecules landed on the same move.

Start with BPC-157. It’s a fifteen-amino-acid fragment of a protein found in gastric juice. Across three decades of animal work, injecting it near a damaged tendon, ligament or gut is reported to speed new-vessel growth at the site and shorten the repair. How it does that, and where its human file actually stands, sits on its own page: BPC-157 and injury recovery.

TB-500 is the grey-market name for synthetic thymosin β4, a 43-amino-acid peptide your cells already use to move and rebuild. In animal wound models it drives cell migration, new blood vessels and calmer inflammation (Philp and Kleinman, 2010). One of its own breakdown fragments carries a separate repair signal on top of that (Wang and colleagues, 2022). The full picture — including the mess over what’s actually in the vial — is on the TB-500 page.

GHK-Cu is the odd one out. It’s a tiny copper-carrying tripeptide your body makes to repair skin and tissue, and makes less of every year. New blood-vessel and nerve outgrowth is one of the actions the research credits it with. More skin-and-longevity than tendon — and it gets its own treatment in the GHK-Cu deep dive.

Same convergence, three times over. Whatever else these molecules do, the blood-vessel signal keeps turning up as the load-bearing claim.

How far the proof actually goes

Now the part the marketing skips.

Almost all of this is animal work. Rats, mostly, in clean lab conditions with controlled doses. That’s a real body of evidence — but it isn’t the same as knowing what happens in a person, at a grey-market dose, over years. The human file is close to empty. BPC-157 has its first proper controlled injury trial recruiting right now, a Phase 2 hamstring-strain study, with no results yet. TB-500 has no registered human tendon trial at all. What gets sold as tendon-repair proof is often a 2020 cell-culture study — cells in a dish on a scaffold, not a tendon, not a person. The honest reviews land in the same place: promising animal mechanism, thin human proof.

And there’s one question this whole class has to answer, because it’s baked into the mechanism.

Healthy adult tissue almost never grows new blood vessels. The body keeps that switch off on purpose — and one of the few things that flips it back on is a tumour trying to build its own blood supply. So the same signal that helps a tendon heal is, in principle, a signal you don’t want reaching a cancer that hasn’t announced itself yet. For BPC-157 that argument is live in print: a 2025 review raised it, and the original research group replied that the peptide’s action looks protective rather than tumour-feeding. The exchange isn’t settled. Both sides are arguing over animal data.

To be fair to these molecules: the animal record is large, and on tumour incidence within the doses tested, largely reassuring. That counts for something. It’s also not a multi-year human safety study in the people actually injecting this stuff, and that study doesn’t exist yet. Hope, with your eyes open.

Where the regulation stands

Two of these three are up for a formal FDA look very soon. BPC-157 and TB-500 are both on the July 23, 2026 Pharmacy Compounding Advisory Committee docket, per Federal Register notice 2026-07361. The reviewed uses are telling. BPC-157 is up for ulcerative colitis, TB-500 for wound healing. Neither one is tendon repair — which is what most of the off-label market is actually buying them for.

GHK-Cu sits on the next wave instead: the second PCAC meeting, scheduled before the end of February 2027, and specifically the injectable form, the one sold off-label. What a PCAC review actually decides is a longer story, and we tell it in what a PCAC review actually is.

One more thing if you get drug-tested. BPC-157 and TB-500 are both on WADA’s prohibited list. GHK-Cu isn’t named — but check the current code on the day, because that can move.

The version worth waiting for

Strip it back and the class-level promise is simple. A signal that tells starved tissue to build itself a better blood supply, so the repairs that currently eat months of your life don’t have to drag. That promise is real. The proof isn’t in yet. And there’s a wide gap between the molecule and the way it’s sold.

The version worth waiting for isn’t a vial ordered off a research-chemical site with a page of forum dosing next to it. It’s a physician who has read the trial data, a US-licensed pharmacy compounding against an indication the FDA has actually reviewed, and a batch assay on every shipment. Wolverine Health is being built to be that version — the legitimate route to something people are already buying the risky way. It stays shut until the regulation opens it. Two dates decide when: July 2026, then February 2027. Put your email in and we’ll flag the day either door actually opens.